AUSTIN, Texas, Dec. 12, 2018 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available.
The interview featuring an overview of BICX’s current news and moves can be heard at https://smallcapvoice.com/12-11-18-smallcapvoice-interview-with-biocorrx-inc-bicx/.
Brady Granier called in to SmallCapVoice.com, Inc. to discuss the progress the Company has made in several key areas, the operational outlook for 2019, the launch of a new weight loss program and more. BioCorRx, Inc. issued a third quarter business update in November outlining where the Company stands with NIDA on their grant application process. In addition, the Company has been working diligently to advance all of its programs in the fight against addiction and specifically the fight against the opioid crisis.
In the interview Granier stated, “Right now, the big focus for the Company is our FDA approval pathway for BICX102, which is our naltrexone implant. We have been working in the naltrexone implant space for many years and that hasn’t changed. What has changed is that now we are seeking FDA approval on one of our naltrexone implants.” In terms of the NIDA (National Institute on Drug Abuse) grant application for BICX102, Granier updated the listeners, “Our grant was reviewed in August and September (2018) and we were recommended for funding by the independent scientific review board. Now the grant is pending for administrative review. We have received a favorable score on our grant as well. We remain confident on the prospect of getting the grant.”
As for 2019 Granier commented, “Our BioCorRx Recovery Program still remains available and is being used by independent treatment providers around the country. We have been focusing on working with several states and municipalities that are interested in the program for fighting this opioid epidemic. We will continue to focus on getting our program widely accepted in 2019.”
About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for their ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/.
About BioCorRx
BioCorRx, Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com